These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16804568)

  • 1. Molecule of the Month. Varenicline tartrate.
    Drug News Perspect; 2006 Apr; 19(3):162. PubMed ID: 16804568
    [No Abstract]   [Full Text] [Related]  

  • 2. Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation.
    Lam S; Patel PN
    Cardiol Rev; 2007; 15(3):154-61. PubMed ID: 17438382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
    Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
    Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical implementation of varenicline as an aid to smoking cessation in clinical practice.
    Tonstad S
    Pneumologia; 2009; 58(3):167-74. PubMed ID: 19817313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new medication for the worst addiction.
    O'Brien CP
    Curr Psychiatry Rep; 2007 Oct; 9(5):345-6. PubMed ID: 17915070
    [No Abstract]   [Full Text] [Related]  

  • 6. The FDA approves new drug for smoking cessation.
    FDA Consum; 2006; 40(4):29. PubMed ID: 17243286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varenicline for smoking cessation: a placebo-controlled, randomized study.
    Wang C; Xiao D; Chan KP; Pothirat C; Garza D; Davies S
    Respirology; 2009 Apr; 14(3):384-92. PubMed ID: 19192221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
    Oncken C; Gonzales D; Nides M; Rennard S; Watsky E; Billing CB; Anziano R; Reeves K
    Arch Intern Med; 2006 Aug 14-28; 166(15):1571-7. PubMed ID: 16908789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A second varenicline trial.
    O'Brien CP
    Curr Psychiatry Rep; 2007 Oct; 9(5):346-7. PubMed ID: 17915071
    [No Abstract]   [Full Text] [Related]  

  • 10. Varenicline (Chantix) for tobacco dependence.
    Med Lett Drugs Ther; 2006 Aug 14-28; 48(1241-1242):66-8. PubMed ID: 16977281
    [No Abstract]   [Full Text] [Related]  

  • 11. A longer course of varenicline therapy improves smoking cessation rates.
    Lee JH; Jones PG; Bybee K; O'Keefe JH
    Prev Cardiol; 2008; 11(4):210-4. PubMed ID: 19476573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of smoking cessation drugs by the Food and Drug Administration.
    Richins C
    Food Drug Law J; 2009; 64(2):277-90. PubMed ID: 19999284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo.
    Garza D; Murphy M; Tseng LJ; Riordan HJ; Chatterjee A
    Biol Psychiatry; 2011 Jun; 69(11):1075-82. PubMed ID: 21295286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Varenicline in smoking cessation.
    Tonstad S; Rollema H
    Expert Rev Respir Med; 2010 Jun; 4(3):291-9. PubMed ID: 20524911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates.
    Hajek P; McRobbie HJ; Myers KE; Stapleton J; Dhanji AR
    Arch Intern Med; 2011 Apr; 171(8):770-7. PubMed ID: 21518946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New drugs; varenicline].
    van Bronswijk H; Dubois EA; Zitman FG; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Nov; 151(45):2503-4. PubMed ID: 18062594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA speeds smoking cessation drug review.
    Kuehn BM
    JAMA; 2006 Feb; 295(6):614. PubMed ID: 16467225
    [No Abstract]   [Full Text] [Related]  

  • 18. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.
    Coe JW; Brooks PR; Vetelino MG; Wirtz MC; Arnold EP; Huang J; Sands SB; Davis TI; Lebel LA; Fox CB; Shrikhande A; Heym JH; Schaeffer E; Rollema H; Lu Y; Mansbach RS; Chambers LK; Rovetti CC; Schulz DW; Tingley FD; O'Neill BT
    J Med Chem; 2005 May; 48(10):3474-7. PubMed ID: 15887955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilization management for smoking cessation pharmacotherapy: varenicline rejected claims analysis.
    Zeng F; Chen CI; Mastey V; Zou KH; Harnett J; Patel BV
    Am J Manag Care; 2010 Sep; 16(9):667-74. PubMed ID: 20873954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of varenicline for smoking cessation.
    Hays JT; Ebbert JO; Sood A
    Am J Med; 2008 Apr; 121(4 Suppl 1):S32-42. PubMed ID: 18342165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.